ETF recommends updating COVID-19 vaccines to target XFG variant
ETF recommends updating COVID-19 vaccines to target XFG variant
ETF recommends updating COVID-19 vaccines to target XFG variant
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
List of centrally authorised products with safety-related changes to the product information
Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking
Quality of medicines: questions and answers - Part 2
Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised
European Medicines Agency’s privacy statement for legal entity and bank account validation
Data protection and privacy at EMA
Champix